News
Is the Quality of Life for Patients with Atrial Fibrillation and Heart Failure Comparable When Treated with Bisoprolol and Digoxin?
The British RATE-AF study, published in December 2020 in the JAMA journal, compared the impact on improving the quality of life in patients with permanent atrial fibrillation (AF) and symptoms of heart failure when administering bisoprolol and low-dose digoxin.
Eletriptan as an effective and safe drug in acute migraine therapy
In the pharmacotherapy of acute migraine attacks, a pharmacologically diverse group of triptans is particularly used. The choice of the right antimigraine drug should be individualized, based on the…
Individualized Prophylaxis with Achieving Higher Minimum Levels as a Possible Path to Optimal Treatment of Hemophilia A
Prophylactic administration of factor VIII (FVIII) concentrate is the standard of care for individuals with severe hemophilia A. Traditionally, the goal of prophylaxis has been to maintain minimum…
Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
The regular webinar of the General Medicine Society of ČLS JEP this spring, besides addressing the current coronavirus situation, also focused on the issue and treatment of pain in its specialized…
Biosimilar Bevacizumab in Patients with Non-Small Cell Lung Cancer
Biosimilar drugs are essentially analogous to generics for biological medicines. The patent protection for the original bevacizumab product will expire in the European Union in 2022. Consequently,…
Position of Generic Drugs in Oncology: What Are Their Main Advantages?
Generics – as is well known – are products containing the same active substance as the original medicinal product, which can enter the market after the patent protection of the original drug has…
Monocyte Distribution Width as a New Indicator of Sepsis in High-Risk Patients
Most septic patients are first encountered in the emergency department, where sepsis detection is often delayed, partly due to a lack of effective biomarkers. The study presented below evaluated the…
New Hematological Biomarker for Early Diagnosis of Sepsis
Sepsis is one of the leading causes of mortality and healthcare expenditure worldwide. Early diagnosis and treatment of septic conditions improve patient prognosis. However, the initial symptoms of…
Interstitial Lung Processes and Their Fibrotic Progression
Interstitial lung processes (ILPs) include more than 200 clinical units that share diffuse involvement of lung tissue and thus have similar clinical, radiological, and functional findings. However,…
Evaluation of Continuity of Care in Patients with mCRC – Baseline Characteristics of Participants in the PROMETCO Study
During this year's World Congress of the European Society for Medical Oncology (ESMO) on gastrointestinal malignancies, the baseline characteristics of participants in the ongoing PROMETCO study, which...
Trifluridine/tipiracil in Real Clinical Practice – Current Data from Spain
Trifluridine/tipiracil is indicated for the treatment of patients with refractory metastatic colorectal cancer (mCRC), where clinical studies have shown it extends overall survival (OS) and progression-free...
Evaluation of Treatment Response in CLL
The size of lymph nodes, liver, spleen, blood cell counts, systemic symptoms... Changes in these indicators provide clear information on whether the disease of chronic lymphocytic leukemia (CLL) has progressed,...
Idiopathic Pulmonary Fibrosis: Can This Disease Be Named More Precisely?
Much about idiopathic pulmonary fibrosis (IPF) is still unknown. Some experts would like to reclassify this disease. What classification options are available? What would a focus on the "progressive…
Brigatinib in the Therapy of ALK-Positive NSCLC in Patients Refractory to Crizotinib Therapy – Results of the Final Analysis of Clinical Studies
Previously published results of clinical studies have shown that in patients refractory to crizotinib therapy, the administration of brigatinib led to a high rate of therapeutic response (systemic…
Brigatinib in the Therapy of ALK-Positive NSCLC – First Results of the J-ALTA Study
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity against ALK gene mutations causing resistance to ALK inhibitor therapy (ALKi). In patients refractory to…